Edition:
United States

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

50.92USD
17 Dec 2018
Change (% chg)

-- (--)
Prev Close
$50.92
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,995,544
52-wk High
$70.04
52-wk Low
$46.95

Select another date:

Mon, Dec 17 2018

UPDATE 1-Taisho said to near $1.6 bln deal for Bristol-Myers's UPSA- Bloomberg

* Taisho's sales of OTC drugs down year-on-year in April-Sept (Adds details on Taisho)

Taisho said to near $1.6 billion deal for Bristol-Myers's UPSA: Bloomberg

Japanese healthcare firm Taisho Pharmaceutical Holdings Co Ltd is said to be close to a $1.6 billion deal for Bristol-Myers Squibb Co's French over-the-counter drugs business UPSA, Bloomberg reported on Sunday, citing sources familiar with the matter.

Taisho said to near $1.6 bln deal for Bristol-Myers's UPSA- Bloomberg

Dec 16 Japanese healthcare firm Taisho Pharmaceutical Holdings Co Ltd is said to be close to a $1.6 billion deal for Bristol-Myers Squibb Co's French over-the-counter drugs business UPSA, Bloomberg reported on Sunday, citing sources familiar with the matter.

Bristol-Myers must face lawsuit alleging underpaid Medicaid rebates

Bristol-Myers Squibb Co must face a whistleblower lawsuit alleging that the drugmaker for years knowingly underpaid rebates the company owed to state Medicaid programs, a federal judge has ruled.

Bristol-Myers Squibb says cancer drug combination fails late-stage trial

Bristol-Myers Squibb Co said on Monday a combination of two of its cancer drugs, being tested as a maintenance therapy, did not meet the main goal of extending the lives of lung cancer patients in a late-stage trial.

UPDATE 1-Bristol-Myers Squibb says cancer drug combination fails late-stage trial

Nov 26 Bristol-Myers Squibb Co said on Monday a combination of two of its cancer drugs, being tested as a maintenance therapy, did not meet the main goal of extending the lives of lung cancer patients in a late-stage trial.

Bristol-Myers Squibb says cancer drug combination fails maintenance trial

Nov 26 Bristol-Myers Squibb Co said on Monday a combination of two of its cancer drugs, being tested as a maintenance therapy, did not meet the main goal of extending the lives of lung cancer patients in a late-stage trial.

Stada, Angelini among final bidders for $1 bln Bristol-Myers' Upsa unit - sources

FRANKFURT/LONDON, Nov 8 German drugmaker Stada and Italian healthcare company Angelini are the only industry players to be shortlisted to make final bids for Bristol-Myers Squibb's French over-the-counter drugs business, four sources close to the deal said.

Merck, Bristol-Myers profits rise on cancer drug sales

Merck & Co Inc and Bristol-Myers Squibb Co posted better-than-expected third quarter profit and raised their 2018 earnings forecasts on Thursday due to strong demand for their rival cancer immuno-oncology treatments.

WRAPUP 1-Merck, Bristol-Myers profits rise on cancer drug sales

Oct 25 Merck & Co Inc and Bristol-Myers Squibb Co posted better-than-expected third quarter profit and raised their 2018 earnings forecasts on Thursday due to strong demand for their rival cancer immuno-oncology treatments.

Select another date: